Thus, we may use these findings to enhance the anticancer impact of these four genes—MBOAT2, CDA, LPCAT2 and B4GALT5—in patients with PACA. The gene discussed is LPCAT2; the disease is permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.